Resources Repository
-
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Cost-Effectiveness Analysis | Health Outcomes | Preferences/Values | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Value of Information | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
BookPublication 1978Swine Flu Affair: Decision-Making on a Slippery Disease
This report from the Institute of Medicine, The Swine Flu Affair: Decision-Making on a Slippery …
This report from the Institute of Medicine, The Swine Flu Affair: Decision-Making on a Slippery Disease, was written to review and critique the decisions made around the 1976 swine flu threat. In 1976, a small group of soldiers at Fort Dix were infected with a swine flu virus that was deemed similar to the virus responsible for the great 1918-19 world-wide flu pandemic. The U.S. government initiated an unprecedented effort to immunize every American against…
Risk Analysis | Decision Analysis | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology | North America -
ArticlePublication 2024Adopting Electric School Buses in the U.S.: Health & Climate Benefits
This article evaluates the health and climate benefits of replacing diesel school buses with electric …
This article evaluates the health and climate benefits of replacing diesel school buses with electric models in the U.S. Despite the high cost of electric buses, their benefits in reducing mortality and childhood asthma, as well as greenhouse gas emissions, could justify the investment. The study quantifies the benefits of replacing an average diesel bus with an electric bus, estimating $84,200 in total benefits per bus, with $40,400 from climate benefits and $43,800 from health…
Benefit-Cost Analysis | Environmental Health | Government/Law | Health/Medicine | North America -
ArticlePublication 2024GBD Study 2021 Estimates: Implications for Health Policy & Research
The article discusses findings from the Global Burden of Diseases, Injuries, and Risk Factors Study …
The article discusses findings from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet, which presents estimates of disease burden worldwide from 1990 to 2021. Despite an overall increase in global disability-adjusted life years (DALYs), age-standardized rates have decreased, particularly for communicable diseases like HIV/AIDS and diarrheal diseases. Post-COVID-19 impacts, including long COVID, are highlighted. GBD aids in tracking progress towards global health goals but its iterative nature…
Health Outcomes | Health/Medicine | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Estimated Reductions in Opioid Overdose Deaths with Sustainment of Public Health Interventions in 4 U.S. States
This study utilizes a decision analytical model to simulate the opioid epidemic in four heavily …
This study utilizes a decision analytical model to simulate the opioid epidemic in four heavily impacted states: Kentucky, Massachusetts, New York, and Ohio. By analyzing the effects of increased initiation and retention of medications for opioid use disorder (MOUDs) and enhanced naloxone distribution over a 2 to 5-year timeframe, the research assesses the potential reduction in opioid overdose deaths (OODs). Results indicate that sustaining a combination of interventions could lead to substantial reductions in OODs,…
Decision Analysis | Mathematical Models | North America -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Cost-Effectiveness Analysis | Mathematical Models | State-Transition | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Cost-Effectiveness Analysis | Mathematical Models | Chronic Disease/Risk | Clinical Care | North America